Drug intelligence / Profile preview

Jinshao capsule

Development stage: Unknown
Lead developer: Guangdong Dexin Pharmaceutical
Administration: Oral

Overview

Jinshao capsule is a Traditional Chinese Medicine (TCM) formulation developed by Guangdong Dexin Pharmaceutical for the treatment of chronic pelvic inflammatory disease (CPID). It is specifically indicated for patients presenting with the TCM syndrome of Qi stagnation, blood stasis, and dampness obstruction (气滞血瘀湿阻证). The therapeutic approach of Jinshao capsule focuses on anti-inflammatory and analgesic effects to manage the sequelae of pelvic inflammatory disease. The drug has undergone Phase III clinical evaluation in China to assess its clinical efficacy and safety profile in this patient population.

Brand names: Jinshao capsule
Other names: Jinshao金芍胶囊

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)

Beyond the preview

Go deeper on Jinshao capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jinshao capsule.

Explore the full profile